| Jun 19 |
Intra-Cellular (ITCI) Up as Second Depression Study Meets Goals
|
| Jun 19 |
Intra-Cellular (ITCI) Soars 9.6%: Is Further Upside Left in the Stock?
|
| Jun 19 |
Intra-Cellular Brightens MDD Outlook With Caplyta Success
|
| Jun 18 |
Intra-Cellular Therapies edges closer to FDA win for Caplyta in depression
|
| Jun 18 |
Intra-Cellular Therapies Eyes $1.7 Billion Opportunity After Phase 3 Win
|
| Jun 18 |
Intra-Cellular gains after late-stage win for mood disorder therapy
|
| Jun 18 |
Intra-Cellular Therapies Announces Positive Topline Results in Second Phase 3 Trial Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder
|
| Jun 18 |
Intra-Cellular depression drug succeeds in second late-stage study
|
| Jun 10 |
Intra-Cellular Therapies to Present at the 45th Annual Goldman Sachs Global Healthcare Conference
|
| Jun 6 |
Why Is Intra-Cellular (ITCI) Up 1.2% Since Last Earnings Report?
|
